E-viri
PDF
Recenzirano
Odprti dostop
-
Herold, Kevan C; Bundy, Brian N; Long, S. Alice; Bluestone, Jeffrey A; DiMeglio, Linda A; Dufort, Matthew J; Gitelman, Stephen E; Gottlieb, Peter A; Krischer, Jeffrey P; Linsley, Peter S; Marks, Jennifer B; Moore, Wayne; Moran, Antoinette; Rodriguez, Henry; Russell, William E; Schatz, Desmond; Skyler, Jay S; Tsalikian, Eva; Wherrett, Diane K; Ziegler, Anette-Gabriele; Greenbaum, Carla J
The New England journal of medicine, 08/2019, Letnik: 381, Številka: 7Journal Article
In this trial, high-risk nondiabetic relatives of patients with type 1 diabetes were randomly assigned to receive teplizumab (an anti-CD3 monoclonal antibody) or placebo and were followed for type 1 diabetes. Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants.
